Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
42 hedge funds and large institutions have $119M invested in Strongbridge Biopharma plc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 16 closing their positions.
76% more call options, than puts
Call options by funds: $51K | Put options by funds: $29K
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
14% less funds holding
Funds holding: 49 → 42 (-7)
20% less capital invested
Capital invested by funds: $149M → $119M (-$29.9M)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.68M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.51M |
| 3 |
2L
22NW LP
Seattle,
Washington
|
+$1.97M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.59M |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$13.9M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.45M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.75M |
| 4 |
Millennium Management
New York
|
-$2.32M |
| 5 |
HCS
Harvest Capital Strategies
San Francisco,
California
|
-$1.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$166K | -34,124 | Closed |
|
52
Citadel Advisors
Miami,
Florida
| – | -$157K | -32,348 | Closed |
|
|
CSS
53
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$92K | -18,986 | Closed |
|
|
ARTA
54
A.R.T. Advisors
New York
| – | -$67K | -13,974 | Closed |
|
|
QSS
55
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$65K | -13,368 | Closed |
|
|
MWNA
56
Marshall Wace North America
New York
| – | -$58K | -11,870 | Closed |
|
|
AAMU
57
Amundi Asset Management US
Boston,
Massachusetts
| – | -$50K | -10,400 | Closed |
|
58
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -220 | Closed |
|
SBBP Hedge Fund Activity: Q4 2018 in Review
42 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2018, worth a combined $119M — down 20% from $149M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SBBP and 9 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was 683 Capital Management, adding an estimated $2.68M. The largest seller was Lyon Street Capital, exiting entirely with an estimated $13.9M sold.
- 42 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2018, down from 49 in Q3 2018.
- Funds reported $119M of Strongbridge Biopharma plc. stock for Q4 2018, down 20% quarter-over-quarter.
- 9 funds opened new Strongbridge Biopharma plc. positions in Q4 2018 and 16 closed out, a net change of -7 holders.
- The largest Strongbridge Biopharma plc. buyer in Q4 2018 was 683 Capital Management, an estimated $2.68M added.
- The largest Strongbridge Biopharma plc. seller in Q4 2018 was Lyon Street Capital, an estimated $13.9M sold.
Based on aggregated 13F filings for Q4 2018.